236 related articles for article (PubMed ID: 22242856)
1. Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.
Ciudin A; Hernandez C; Simó R
Curr Top Med Chem; 2012; 12(6):585-604. PubMed ID: 22242856
[TBL] [Abstract][Full Text] [Related]
2. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Simó R; Rodriguez A; Caveda E
Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
5. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
6. Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.
Barbieri M; Di Filippo C; Esposito A; Marfella R; Rizzo MR; D'Amico M; Ferraraccio F; Di Ronza C; Duan SZ; Mortensen RM; Rossi F; Paolisso G
PLoS One; 2012; 7(4):e35999. PubMed ID: 22563432
[TBL] [Abstract][Full Text] [Related]
7. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
[TBL] [Abstract][Full Text] [Related]
8. Effects of PPARγ ligands on vascular tone.
Salomone S; Drago F
Curr Mol Pharmacol; 2012 Jun; 5(2):282-91. PubMed ID: 22122458
[TBL] [Abstract][Full Text] [Related]
9. PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.
Abbas A; Blandon J; Rude J; Elfar A; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2012 Jun; 10(2):124-34. PubMed ID: 22471957
[TBL] [Abstract][Full Text] [Related]
10. [Protective role of PPARgamma agonists against cardiovascular disease].
Yamagishi S
Nihon Rinsho; 2010 Feb; 68(2):307-11. PubMed ID: 20158101
[TBL] [Abstract][Full Text] [Related]
11. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
12. Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
Goto T; Nakayama R; Yamanaka M; Takata M; Takazawa T; Watanabe K; Maruta K; Nagata R; Nagamine J; Tsuchida A; Kato H
Exp Clin Endocrinol Diabetes; 2015 Sep; 123(8):492-9. PubMed ID: 26011171
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Tureyen K; Kapadia R; Bowen KK; Satriotomo I; Liang J; Feinstein DL; Vemuganti R
J Neurochem; 2007 Apr; 101(1):41-56. PubMed ID: 17394460
[TBL] [Abstract][Full Text] [Related]
14. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
Higgins LS; Depaoli AM
Am J Clin Nutr; 2010 Jan; 91(1):267S-272S. PubMed ID: 19906796
[TBL] [Abstract][Full Text] [Related]
15. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
16. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.
Garcia-Vallvé S; Guasch L; Tomas-Hernández S; del Bas JM; Ollendorff V; Arola L; Pujadas G; Mulero M
J Med Chem; 2015 Jul; 58(14):5381-94. PubMed ID: 25734377
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones and PPARγ agonists: time for a reassessment.
Cariou B; Charbonnel B; Staels B
Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
[TBL] [Abstract][Full Text] [Related]
19. Revisiting PPARγ as a target for the treatment of metabolic disorders.
Choi SS; Park J; Choi JH
BMB Rep; 2014 Nov; 47(11):599-608. PubMed ID: 25154720
[TBL] [Abstract][Full Text] [Related]
20. A step ahead of PPARγ full agonists to PPARγ partial agonists: therapeutic perspectives in the management of diabetic insulin resistance.
Chigurupati S; Dhanaraj SA; Balakumar P
Eur J Pharmacol; 2015 May; 755():50-7. PubMed ID: 25748601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]